Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma
Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patients.